I held on to my shares of Gilead Sciences (NASDAQ: GILD) for a long time.
When sales for the big biotech's hepatitis C franchise sank a few years ago, pulling the stock down along the way, I stayed the course. When Gilead's seemingly promising nonalcoholic steatohepatitis (NASH) candidate selonsertib bombed in a late-stage study last year, I didn't panic. When Gilead began replacing nearly all of its top executives, I remained optimistic.
In fact, I was a champion for the biotech stock. But that's no longer true. I sold all of my shares several days ago. Here's why I finally gave up on Gilead.
Source Fool.com